Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Leading small molecules for the selective protein clearance in ER disorders

Obiettivo

Many severe genetic and age-related diseases are driven by the accumulation of misfolded proteins within the endoplasmic reticulum, leading to chronic cellular stress, tissue damage and organ failure. Despite major advances in targeted protein degradation, no current technology can selectively eliminate toxic proteins residing inside this cellular compartment. As a result, patients affected by the so-called ER-storage diseases (e.g. collagenopathies, corneal dystrophies or serpinopathies) still lack therapies that address the root cause of their condition.

Building on discoveries from the ERC AUTO-SELECT project, this Proof of Concept aims to translate the identification of ER-phagy as a selective, mutation-agnostic ER quality-control pathway into a therapeutic strategy. The project will develop and validate small molecules selectively activating ER-phagy and promoting the removal of disease-causing proteins without inducing global autophagy. This represents a first-in-class approach to degrade toxic ER-resident proteins that are inaccessible to existing modalities.

The PoC will confirm mechanism of action, demonstrate clearance of pathogenic proteins in validated disease models, and assess selectivity and cellular safety. In parallel, intellectual property will be consolidated within a dedicated spin-out, Eracle Bio, and aligned with a structured partnering and licensing strategy supported by an experienced life sciences investor. By delivering validated lead compounds and a partnering-ready data package, the project creates a clear pathway from ERC-funded discovery to industrial collaboration and clinical translation.

If successful, this work will establish a new therapeutic paradigm focused on compartment-specific protein degradation and open scalable opportunities for treating multiple currently untreatable diseases, with significant impact for both science and society.

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

FONDAZIONE TELETHON ETS
Contributo netto dell'UE
€ 150 000,00
Costo totale
Nessun dato

Beneficiari (1)